Physician
Neurology
Dr. James J. Vornov, MD
James Vornov is an expert in the field of Neurology. He attended Emory University School of Medicine. Emory University School of Medicine has a rank of 23 in research and a 42 in primary care James Vornov is also a published doctor. He has 35 publication published. The most recent publication is: Cerebellar top-of-the-basilar syndrome.
Publications
- Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism.
- Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers.
- Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion.
- Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers.
- The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.
- Retraction. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers.
- Retraction. Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion.
- Retraction. AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN, Part 1: pharmacokinetics.
- Retration. AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN, Part 2: pharmacodynamics a...
- The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801.
- Enhancement of NMDA receptor-mediated neurotoxicity in the hippocampal slice by depolarization and ischemia.
- Glutamate neurotoxicity and the inhibition of protein synthesis in the hippocampal slice.
- The non-excitatory mechanisms of glutamate induced neurotoxicity.
- Direct observation of the agonist-specific regional vulnerability to glutamate, NMDA, and kainate neurotoxicity in organotypic hippocampal cultures.
- Selective release of N-acetylaspartylglutamate from rat optic nerve terminals in vivo.
- Noradrenergic hyperinnervation of the motor trigeminal nucleus: alterations in membrane properties and responses to synaptic input.
- Brainstem projections to the normal and noradrenergically hyperinnervated trigeminal motor nucleus.
- Neurotoxicity of acute glutamate transport blockade depends on coactivation of both NMDA and AMPA/Kainate receptors in organotypic hippocampal cultures.
- Toxic NMDA-receptor activation occurs during recovery in a tissue culture model of ischemia.
- Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture model of ischemia.
- Protective effects of extracellular acidosis and blockade of sodium/hydrogen ion exchange during recovery from metabolic inhibition in neuronal tissue culture.
- Regional vulnerability to endogenous and exogenous oxidative stress in organotypic hippocampal culture.
- Ion channels and exchangers that mediate ischemic neuronal injury.
- Cerebellar top-of-the-basilar syndrome.
- Inhibition of virus-induced neuronal apoptosis by Bax.
- Toxicity induced by a polyglutamated folate analog is attenuated by NAALADase inhibition.
- Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
- Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG.
- N-Acetylated alpha-linked acidic dipeptidase converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin.
- Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats.
- Glutamate carboxypeptidase II inhibition as a novel therapeutic target.
- AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics.
- AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 2): pharmacodynamics and safety.
- Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
Schools
Emory University
Doctors Specialties
- Neurology
Accepted Insurances
Education
-
Johns Hopkins University -
Emory University -
Emory University School of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Christopher B. Oakley, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brett M. Morrison, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott D. Newsome, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barry J. Gordon, MD |
|
|
Dr. Jaishri O. Blakeley, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daniel M. Harrison, MD |
|
|
Dr. Lisa Shulman, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Raya Massoud, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John A. Talbott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ernst F L. Niedermeyer |